Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

CATALYST PHARMACEUTICALS INC (CPRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
3.37(c) 3.41(c) 3.47(c) 3.53(c) 3.43(c) Last
651 524 292 218 323 122 359 664 314 339 Volume
+2.90% +1.19% +1.76% +1.73% -2.83% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -18,8 M
Net income 2017 -18,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,27 M
EBIT 2018 -26,1 M
Net income 2018 -25,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 41,8x
Capitalization 304 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
02/14CATALYST PHARMACEUTICALS : Announces Plans to Resubmit New Drug Application for ..
AQ
02/13CATALYST PHARMACEUTICALS : Announces Plans to Resubmit New Drug Application for ..
AQ
02/12CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
AQ
02/12CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
AQ
02/12Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for..
GL
02/07Catalyst Pharmaceuticals to Present at Two Upcoming Investor Conferences
GL
01/08CATALYST PHARMACEUTICALS, INC. : Other Events (form 8-K)
AQ
2017CATALYST PHARMACEUTICALS : Announces Closing of Previously Announced Public Offe..
AQ
2017CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
AQ
2017CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
02/16Two men given more time in jail than they expected for the stabbing death of .. 
02/15Graham on DHS torching bipartisan Senate immigration plan: "Who the hell wrot..
55
02/15$CPRX New SEC Document(s) for Catalyst Pharmaceuticals, Inc. From our Stock N.. 
02/13$CPRX New SEC Document(s) for Catalyst Pharmaceuticals, Inc. From our Stock N.. 
02/13$CPRX  
More tweets
Qtime:117
News from SeekingAlpha
02/14YOUR DAILY PHARMA SCOOP : Akebia Update, Rexahn Data, Concert Commences Enrollme.. 
02/13Catalyst Pharmaceutical (CPRX) Presents At BIO CEO & Investor Conference - Sl.. 
02/12Catalyst Bio on track to resubmit Firdapse NDA next month 
02/10STOCKS TO WATCH : Digging For Gems In The Shakeout 
02/09Key events next week - healthcare 
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,19 $
Spread / Average Target 75%
EPS Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICALS INC-11.25%304
GILEAD SCIENCES14.21%106 851
VERTEX PHARMACEUTICALS4.94%39 772
REGENERON PHARMACEUTICALS-12.04%35 529
BIOVERATIV INC91.99%11 201
GENMAB4.28%11 055